| Date | Title | Description | |
|---|---|---|---|
| 27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
| 27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 08 Nov 2023 | On P&L | The Company releases the press release related to the first nine months of 2023 financial results | Download |
| 08 Nov 2023 | On P&L | The Company releases the first nine months 2023 financial results presentation | Download |
| 26 Jul 2023 | On P&L | The Company releases the press release related to the first half 2023 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
| 09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
| 15 Dec 2022 | On Corporate Governance | The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. | Download |
| 04 Oct 2022 | On business and financial situation | The Company informs that it has signed a joint venture agreement with Càrniques Ceirà and Grupo Costa to construct a plant for the production of compounds of high technological value. | Download |
| 03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |